The effect of iron in MRI and transverse relaxation of amyloid-beta plaques in Alzheimer's disease

NMR in Biomedicine

Volumn 28, Issue 3, 2015, Pages 297-305

  Meadowcroft, Mark D ^a   Peters, Douglas G ^a   Dewal, Rahul P ^a   Connor, James R ^a   Yang, Qing X ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; A ; Chelation; Deferoxamine; Iron; MRI; Plaques

Indexed keywords

AMINES; CHELATION; DISEASE CONTROL; GLYCOPROTEINS; IRON; MAGNETIC RESONANCE IMAGING; NEURODEGENERATIVE DISEASES; TISSUE;

ALZHEIMER'S DISEASE; AMYLOID BETAS; DEFEROXAMINE; PLAQUES; PROTON RELAXATION; RELAXATION MECHANISM; TRANSVERSE RELAXATION; TRANSVERSE RELAXATION RATE;

IRON METALLOGRAPHY;

AMYLOID BETA PROTEIN; DEFEROXAMINE; IRON; SODIUM CHLORIDE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CONTROLLED STUDY; ENTORHINAL CORTEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IRON CHELATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; AGED; CASE CONTROL STUDY; METABOLISM; PATHOLOGY;

AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; DEFEROXAMINE; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; PLAQUE, AMYLOID;

EID: 84924072485     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3247     Document Type: Article

References (48)

1. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem. J. 2011; 434(3): 365-381.
2. Tsuji Y, Ayaki H, Whitman SP, Morrow CS, Torti SV, Torti FM. Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol. Cell Biol. 2000; 20(16): 5818-5827.
3. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 1958; 3(1): 41-51.
4. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004; 5(11): 863-873.
5. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J. Neurosci. Res.. 1992; 31(1): 75-83.
6. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci.. 1998; 158(1): 47-52.
7. Meadowcroft MD, Connor JR, Smith MB, Yang QX. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J. Magn. Reson. Imaging, 2009; 29(5): 997-1007.
8. Collingwood JF, Chong RK, Kasama T, Cervera-Gontard L, Dunin-Borkowski RE, Perry G, Posfai M, Siedlak SL, Simpson ET, Smith MA, Dobson J. Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer's plaque core material. J. Alzheimers Dis. 2008; 14(2): 235-245.
9. Bodovitz S, Falduto MT, Frail DE, Klein WL. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J. Neurochem. 1995; 64(1): 307-315.
10. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell, 2010; 142(6): 857-867.
11. Everett J, Cespedes E, Shelford LR, Exley C, Collingwood JF, Dobson J, van der Laan G, Jenkins CA, Arenholz E, Telling ND. Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide beta-amyloid (1-42). J. R. Soc. Interface, 2014; 11(95): 20140165.
12. Bousejra-ElGarah F, Bijani C, Coppel Y, Faller P, Hureau C. Iron(II) binding to amyloid-beta, the Alzheimer's peptide. Inorg. Chem. 2011; 50(18): 9024-9030.
13. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging, 2002; 23(6): 1031-1038.
14. Harman D. Alzheimer's disease pathogenesis: role of aging. Ann. N. Y. Acad. Sci. 2006; 1067: 454-460.
15. Smith MA, Sayre LM, Perry G. Is Alzheimer's a disease of oxidative stress? Alzheimer's Dis. Rev. 1996; 1: 63-67.
16. Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB, Perry G. Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J. Alzheimers Dis. 2004; 6(2): 165-169.
17. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U. S. A., 1997; 94(18): 9866-9868.
18. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J. Neurosci. Res. 2007; 85(14): 3036-3040.
19. Khan A, Dobson JP, Exley C. Redox cycling of iron by Abeta42. Free Radic. Biol. Med. 2006; 40(4): 557-569.
20. Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology, 2000; 149(1): 43-50.
21. Koppenol WH. The Haber-Weiss cycle-70years later. Redox Rep.. 2001; 6(4): 229-234.
22. Hautot D, Pankhurst QA, Khan N, Dobson J. Preliminary evaluation of nanoscale biogenic magnetite in Alzheimer's disease brain tissue. Proc. Biol. Sci. 2003; 270(Suppl. 1): S62-S64.
23. Everett J, Cespedes E, Shelford LR, Exley C, Collingwood JF, Dobson J, van der Laan G, Jenkins CA, Arenholz E, Telling ND. Evidence of redox-active iron formation following aggregation of ferrihydrite and the Alzheimer's disease peptide beta-amyloid. Inorg. Chem. 2014; 53(6): 2803-2809.
24. 2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp. Neurol. 2003; 180(2): 144-155.
25. Connor JR, Milward EA, Moalem S, Sampietro M, Boyer P, Percy ME, Vergani C, Scott RJ, Chorney M. Is hemochromatosis a risk factor for Alzheimer's disease? J. Alzheimers Dis. 2001; 3(5): 471-477.
26. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry, 1999; 38(24): 7609-7616.
27. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-beta in Alzheimer's disease. Int. J. Exp. Pathol. 2005; 86(3): 147-159.
28. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G. Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid. Redox Signal. 2000; 2(3): 413-420.
29. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem. 2000; 74(1): 270-279.
30. Moses WW. Fundamental limits of spatial resolution in PET. Nucl. Instrum. Methods Phys. Res. A, 2011; 648(Supplement 1): S236-S240.
31. Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA. Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem. Res. 2005; 30(2): 201-205.
32. Jack CR Jr, Garwood M, Wengenack TM, Borowski B, Curran GL, Lin J, Adriany G, Grohn OH, Grimm R, Poduslo JF. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 2004; 52(6): 1263-1271.
33. Meadowcroft MD, Zhang S, Liu W, Park BS, Connor JR, Collins CM, Smith MB, Yang QX. Direct magnetic resonance imaging of histological tissue samples at 3.0T. Magn. Reson. Med. 2007; 57(5): 835-841.
34. Kwiatkowski JL. Real-world use of iron chelators. Hematol. Am. Soc. Hematol. Educ. Program 2011; 1: 451-458.
35. Peter HH. [Iron chelation. Biological significance and medical application]. Schweiz. Med. Wochenschr. 1983; 113(40): 1428-1433.
36. Mosher TJ, Smith HE, Collins C, Liu Y, Hancy J, Dardzinski BJ, Smith MB. Change in knee cartilage T2 at MR imaging after running: a feasibility study. Radiology, 2005; 234(1): 245-249.
37. Denk C, Rauscher A. Susceptibility weighted imaging with multiple echoes. J. Magn. Reson. Imaging 2010; 31(1): 185-191.
38. Deistung A, Rauscher A, Sedlacik J, Stadler J, Witoszynskyj S, Reichenbach JR. Susceptibility weighted imaging at ultra high magnetic field strengths: theoretical considerations and experimental results. Magn. Reson. Med. 2008; 60(5): 1155-1168.
39. LeVine SM. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res. 1997; 760(1-2): 298-303.
40. Hohn A, Jung T, Grimm S, Grune T. Lipofuscin-bound iron is a major intracellular source of oxidants: role in senescent cells. Free Radic. Biol. Med. 2010; 48(8): 1100-1108.
41. D'Andrea MR, Nagele RG, Gumula NA, Reiser PA, Polkovitch DA, Hertzog BM, Andrade-Gordon P. Lipofuscin and Abeta42 exhibit distinct distribution patterns in normal and Alzheimer's disease brains. Neurosci. Lett. 2002; 323(1): 45-49.
42. Wengenack TM, Reyes DA, Curran GL, Borowski BJ, Lin J, Preboske GM, Holasek SS, Gilles EJ, Chamberlain R, Marjanska M, Jack CR Jr, Garwood M, Poduslo JF. Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. Neuroimage 2011; 54(1): 113-122.
43. Chamberlain R, Wengenack TM, Poduslo JF, Garwood M, Jack CR Jr. Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. Curr. Med. Imaging Rev. 2011; 7(1): 3-7.
44. Chavhan GB, Babyn PS, Thomas B, Shroff MM, Haacke EM. Principles, techniques, and applications of T2*-based MR imaging and its special applications. Radiographics 2009; 29(5): 1433-1449.
45. Fullerton GD, Finnie MF, Hunter KE, Ord VA, Cameron IL. The influence of macromolecular polymerization of spin-lattice relaxation of aqueous solutions. Magn. Reson. Imaging 1987; 5(5): 353-370.
46. Lu PH, Lee GJ, Shapira J, Jimenez E, Mather MJ, Thompson PM, Bartzokis G, Mendez MF. Regional differences in white matter breakdown between frontotemporal dementia and early-onset Alzheimer's disease. J. Alzheimer's Dis. 2014; 39(2): 261-269.
47. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging 2009; 32(8): 1341-1371.
48. van Duijn S, Nabuurs RJ, van Rooden S, Maat-Schieman ML, van Duinen SG, van Buchem MA, van der Weerd L, Natte R. MRI artifacts in human brain tissue after prolonged formalin storage. Magn. Reson. Med. 2011; 65(6): 1750-1758.